Sage Therapeutics Inc
(FRA:SG7)
€
5.79
-0.394 (-6.37%)
Market Cap: 328.82 Mil
Enterprise Value: -195.46 Mil
PE Ratio: 0
PB Ratio: 0.70
GF Score: 45/100 
SAGE Therapeutics Inc at Stifel Healthcare Conference Transcript
Nov 19, 2019 / 03:20PM GMT
Release Date Price:
€130
(-0.76%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Thanks. My name is Paul Matteis. I'm a biotech analyst at Stifel. Happy to be hosting the Sage team with me, Kimi Iguchi, CFO; Steve Kanes, Chief Medical Officer. I think we'll just kick it off. I'm sure everyone knows Sage quite well. But maybe, Steve, do you want to just briefly talk about the 217 clinical studies, timing of MOUNTAIN enrollment, when it was completed and what the next catalysts are? Or do you want to do it, Kimi?
Kimi E. Iguchi
Sage Therapeutics, Inc. - CFO & Treasurer
No, but let me jump in. Maybe I can just give a couple of highlights from our earnings call.
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Please. Yes. Go ahead.
Kimi E. Iguchi
Sage Therapeutics, Inc. - CFO & Treasurer
I think because I know
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers